Kaya Ltd

- The company has board approval for a rights issue aiming to raise Rs.300 Crores. - The rights issue is in progress; due diligence is underway and will be submitted to the regulatory authority. - Management has requested more time to close the rights issue but confirmed it is on track. - On debt, current net debt stands at Rs.117 Crores consolidated with cash around Rs.75 Crores. - Recent cash drawdown was primarily for expansion strategies; the company is deploying resources towards growth. - Management indicated current cash flow is sufficient, and no immediate need for additional cash infusion was noted.

- Kaya Limited is actively investing in upgrading clinic infrastructure, reflected by renovating 11 clinics YTD and relocating 4 clinics in the year, with relocated clinics seeing 73% growth this quarter. - Refurbishment costs per clinic vary from under Rs.10 lakhs for simple refurbishments up to Rs.70-80 lakhs for relocations, depending on size and complexity. - The company invested in 39 new derma technology machines in Q3, including anti-aging, acne scar, and hair care devices, totaling 102 new machines added recently. - Focus on improving clinic technology and customer experience with significant investments in contemporary technology and machines post-COVID. - Strategy includes expanding footprint by adding 6-8 new clinics in the short term, primarily in tier 2 cities and suburbs of major cities. - Ongoing investment in the D2C and omni-channel product business, including development of own nutraceutical brand.

- Kaya India is experiencing strong revenue growth, with clinic growth at 19% YoY and 17% YTD. - Product business growth is robust at 24% YTD, driven by hair care, skincare, nutraceuticals, and omni-channel initiatives. - Renovation and relocation of clinics are leading to higher collections, with relocated clinics growing 73% in Q3 and renovated clinics growing 16% YTD. - New verticals like body treatments contribute around 6% of business, showing strong traction. - Expansion into tier 2 cities and suburban areas is ongoing, with 4 clinics opened under a new model and plans to open 6-8 clinics in the short term. - Investment in technology and customer experience is expected to sustain growth. - Focus on product growth with new launches and nutraceuticals, targeting higher product sales contribution over medium term. - Management anticipates continued growth and eventually turning profitable if the current trajectory sustains.

- Kaya has shown positive momentum with double-digit growth in India clinics (19% YoY) and product growth of 26% YoY in Q3 FY2024. - EBITDA improved significantly, with a 67% increase in Q3 to Rs.11.2 Crores and narrowing loss after tax to Rs.9 Crores from Rs.17.6 Crores last year. - The company is pursuing sustainable growth via clinic renovations, new technology investments, and expanding product lines (nutraceuticals, hair care, body vertical). - Management indicates a path to profitability if current growth trends continue but refrains from giving exact timelines. - Expansion into tier 2 cities and omni-channel retail is expected to diversify revenue streams and improve margins. - New verticals and increased customer acquisition efforts aim to boost top-line and eventually improve EPS. - Rights issue underway to raise Rs.300 Crores to fuel expansion and strengthen balance sheet. - Overall, with continued execution, Kaya is likely to turn PAT positive in the near future.

The transcript provided does not explicitly mention current or expected order book or pending orders for Kaya Limited. However, relevant insights related to growth, expansion, and business traction include: - Kaya India clinics experienced strong growth with 19% revenue growth in Q3 and 17% YTD. - The company renovated 11 clinics YTD and relocated 4 clinics, with renovated clinics showing 16% growth. - Around 6 to 8 new clinics planned for the short term. - Expansion focus on Tier 2 cities and suburban clusters with ongoing identification of new clinic locations. - Continued investment in product business with 24% growth over last 9-10 months, including D2C and omni-channel. - No specific quantitative details provided on order book or pending orders. Therefore, no explicit order book or pending orders data is disclosed in this call.